Ilias Karaiskos

List of Publications by Citations

55 papers	3,049 citations	28 h-index	55 g-index
66 ext. papers	3,820 ext. citations	7.3 avg, IF	5.3 L-index

#	Paper	IF	Citations
55	Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3430-6	5.9	396
54	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). *Pharmacotherapy*, **2015**, 35, 10-39	5.8	280
53	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. *Lancet Infectious Diseases, The*, **2017**, 17, 726-734	25.5	268
52	Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 1351-70	4	189
51	Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4241-9	5.9	171
50	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. *International Journal of Antimicrobial Agents*, **2014**, 43, 52-9	14.3	155
49	The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. *Frontiers in Public Health*, **2019**, 7, 151	6	107
48	Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. *International Journal of Antimicrobial Agents*, **2013**, 41, 499-508	14.3	102
47	Management of KPC-producing Klebsiella pneumoniae infections. *Clinical Microbiology and Infection*, **2018**, 24, 133-144	9.5	98
46	A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4159-69	5.9	96
45	Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2388-90	5.9	92
44	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 7240-8	5.9	76
43	Colistin: still a lifesaver for the 21st century?. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 59-71	5.5	66
42	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. *Mayo Clinic Proceedings*, **2016**, 91, 1362-1371	6.4	66
41	Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 668-71	5.9	65
40	Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. *Expert Opinion on Drug Metabolism and Toxicology* , **2019**, 15, 133-149	5.5	49
39	Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. *BMC Infectious Diseases*, **2019**, 19, 167	4	48

38	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6471-6	5.9	48
37	Successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. *International Journal of Antimicrobial Agents*, **2013**, 41, 480-3	14.3	39
36	Epidemiology and resistance phenotypes of carbapenemase-producing in Greece, 2014 to 2016. *Eurosurveillance*, **2018**, 23,	19.8	39
35	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. *Journal of Critical Care*, **2011**, 26, 331.e1-7	4	37
34	Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. *European Journal of Clinical Microbiology and Infectious Diseases*, **2017**, 36, 1305-1315	5.3	36
33	High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. *International Journal of Antimicrobial Agents*, **2015**, 45, 90-3	14.3	34
32	Carbapenem-Sparing Strategies for ESBL Producers: When and How. *Antibiotics*, **2020**, 9,	4.9	33
31	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1672-80	5.1	33
30	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. *Clinical Infectious Diseases*, **2017**, 65, 1615-1623	11.6	33
29	Plazomicin: an investigational therapy for the treatment of urinary tract infections. *Expert Opinion on Investigational Drugs*, **2015**, 24, 1501-11	5.9	30
28	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae. *Infection Control and Hospital Epidemiology*, **2018**, 39, 660-667	2	29
27	Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. *International Journal of Antimicrobial Agents*, **2010**, 35, 62-7	14.3	28
26	Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant Klebsiella pneumoniae. *Microbial Genomics*, **2018**, 4,	4.4	28
25	Combination therapy for extensively-drug resistant gram-negative bacteria. *Expert Review of Anti-Infective Therapy*, **2017**, 15, 1123-1140	5.5	26
24	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae. *International Journal of Antimicrobial Agents*, **2018**, 52, 577-585	14.3	23
23	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. *International Journal of Antimicrobial Agents*, **2016**, 48, 337-41	14.3	21
22	In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016. *European Journal of Clinical Microbiology and Infectious Diseases*, **2019**, 38, 1143-1150	5.3	21
21	Oral fosfomycin for the treatment of chronic bacterial prostatitis. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1430-1437	5.1	19

20	Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. *Eurosurveillance*, **2020**, 25,	19.8	17
19	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. *European Journal of Clinical Microbiology and Infectious Diseases*, **2021**, 40, 219-224	5.3	16
18	Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant Klebsiella pneumoniae isolates from individual patients before and after colistin treatment. *Journal of Infection*, **2019**, 79, 312-321	18.9	14
17	Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 775-783	5.1	14
16	Carbapenemase producing : implication on future therapeutic strategies. *Expert Review of Anti-Infective Therapy*, **2021**, 1-17	5.5	10
15	Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013. *Infectious Diseases*, **2016**, 48, 287-292	3.1	9
14	Large vessel vasculitis in a patient with acute Q-fever: A case report. *IDCases*, **2014**, 1, 56-9	2	9
13	Severe dysphagia as the presenting symptom of Wernicke-Korsakoff syndrome in a non-alcoholic man. *Neurological Sciences*, **2008**, 29, 45-6	3.5	9
12	De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 3665-3674	5.1	9
11	Nosocomial dissemination of Providencia stuartii isolates producing extended-spectrum β-lactamases VEB-1 and SHV-5, metallo-β-lactamase VIM-1, and RNA methylase RmtB. *Journal of Global Antimicrobial Resistance*, **2013**, 1, 115-116	3.4	8
10	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. *International Journal of Antimicrobial Agents*, **2017**, 50, 664-672	14.3	8
9	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	7
8	Multidrug-resistant : mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations. *Expert Review of Anti-Infective Therapy*, **2021**, 19, 1457-1468	5.5	7
7	Evaluation of ComASP® Colistin (formerly SensiTest® Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant Klebsiella pneumoniae isolates. *Journal of Global Antimicrobial Resistance*,	3.4	6
6	Point-prevalence survey of healthcare facility-onset healthcare-associated Clostridium difficile infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. *PLoS ONE*, **2017**, 12, e0182799	3.7	5
5	In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2164-2172	5.1	4
4	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR Klebsiella pneumoniae clinical isolates from the same patients before and after colistin treatment. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2852-2863	5.1	4
3	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. *JMIR MHealth and UHealth*, **2020**, 8, e20525	5.5	1

2	Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing Klebsiella pneumoniae isolates. *Journal of Global Antimicrobial Resistance*, **2020**, 20, 98-104	3.4	1
1	Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulization of CMS among patients with ventilator-associated pneumonia.. *International Journal of Antimicrobial Agents*, **2022**, 106588	14.3	1